[go: up one dir, main page]

MX2019011386A - Compuestos, composiciones farmaceuticas y un metodo para la profilaxis y tratamiento del proceso de adhesion. - Google Patents

Compuestos, composiciones farmaceuticas y un metodo para la profilaxis y tratamiento del proceso de adhesion.

Info

Publication number
MX2019011386A
MX2019011386A MX2019011386A MX2019011386A MX2019011386A MX 2019011386 A MX2019011386 A MX 2019011386A MX 2019011386 A MX2019011386 A MX 2019011386A MX 2019011386 A MX2019011386 A MX 2019011386A MX 2019011386 A MX2019011386 A MX 2019011386A
Authority
MX
Mexico
Prior art keywords
treatment
compounds
pharmaceutical compositions
prophylaxis
adhesions
Prior art date
Application number
MX2019011386A
Other languages
English (en)
Other versions
MX382507B (es
Inventor
Gennadievich Shurygin Mikhail
Aleksandrovna Shurygina Irina
Original Assignee
Pharmasyntez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2011119848/15A external-priority patent/RU2011119848A/ru
Application filed by Pharmasyntez filed Critical Pharmasyntez
Publication of MX2019011386A publication Critical patent/MX2019011386A/es
Publication of MX382507B publication Critical patent/MX382507B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • C08G73/0206Polyalkylene(poly)amines
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/0605Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/04Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors
    • C08L79/06Polyhydrazides; Polytriazoles; Polyamino-triazoles; Polyoxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere al campo de la farmacéutica, la medicina clínica y experimental y la medicina veterinaria, y en particular, a nuevos compuestos inhibidores de una quinasa MAP p38 con una estructura de tipo (I) - (VII) que puede ser utilizada para el tratamiento y la prevención de adherencias. La invención describe composiciones farmacéuticas que contienen una cantidad efectiva de la sustancia SB203580 o uno de los compuestos de tipo (I) - (VII) o una combinación de los mismos y un portador, diluyente o excipiente farmacéuticamente aceptable. También, se describe el uso de la sustancia SB203580 como un agente que tiene actividad anti-adherencia. Además se describe: un método para la prevención y/o tratamiento de una enfermedad o condición en el que existe la posibilidad de formación y/o crecimiento de adherencias lo que hace posible prescindir de la administración adicional de una preparación en el período postoperatorio.
MX2019011386A 2011-05-17 2012-05-17 Compuestos, composiciones farmaceuticas y un metodo para la profilaxis y tratamiento del proceso de adhesion. MX382507B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2011119848/15A RU2011119848A (ru) 2011-05-17 2011-05-17 Способ профилактики спайкообразования
RU2011153043 2011-12-26
PCT/IB2012/052483 WO2012156938A1 (ru) 2011-05-17 2012-05-17 Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса

Publications (2)

Publication Number Publication Date
MX2019011386A true MX2019011386A (es) 2019-10-30
MX382507B MX382507B (es) 2025-03-13

Family

ID=47176372

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013013409A MX369019B (es) 2011-05-17 2012-05-17 Compuestos inhibidores de quinasa map p38 como agentes antiadherencias, conjugados con una unidad estructural de polímeros básicos solubles en agua y su uso para el tratamiento o prevención de adherencias en tejidos u órganos.
MX2019011386A MX382507B (es) 2011-05-17 2012-05-17 Compuestos, composiciones farmaceuticas y un metodo para la profilaxis y tratamiento del proceso de adhesion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013013409A MX369019B (es) 2011-05-17 2012-05-17 Compuestos inhibidores de quinasa map p38 como agentes antiadherencias, conjugados con una unidad estructural de polímeros básicos solubles en agua y su uso para el tratamiento o prevención de adherencias en tejidos u órganos.

Country Status (31)

Country Link
US (2) US10172952B2 (es)
EP (2) EP2716684B1 (es)
JP (2) JP5936683B2 (es)
KR (2) KR20170034950A (es)
CN (1) CN103534293B (es)
AP (1) AP3694A (es)
AU (3) AU2012257347A1 (es)
BR (1) BR112013029616B1 (es)
CA (1) CA2836268C (es)
CL (1) CL2013003305A1 (es)
CO (1) CO6801779A2 (es)
CR (1) CR20130600A (es)
CY (1) CY1122190T1 (es)
DK (1) DK2716684T3 (es)
DO (1) DOP2013000266A (es)
EA (1) EA025493B1 (es)
GE (1) GEP201706614B (es)
IL (1) IL229423B (es)
LT (1) LT2716684T (es)
MA (1) MA35189B1 (es)
MX (2) MX369019B (es)
NI (1) NI201300124A (es)
PE (1) PE20141161A1 (es)
PH (1) PH12013502381B1 (es)
PL (1) PL2716684T3 (es)
RS (1) RS59382B1 (es)
RU (1) RU2582975C2 (es)
SI (1) SI2716684T1 (es)
SV (1) SV2013004582A (es)
WO (1) WO2012156938A1 (es)
ZA (1) ZA201308542B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170034950A (ko) * 2011-05-17 2017-03-29 조인트 스톡 컴퍼니 “파르마신세즈” 부착과정의 예방과 치료를 위한 p38 MAP 키나아제 저해제 조성물
RU2745965C1 (ru) * 2020-11-23 2021-04-05 Галина Анатольевна Пучкина Способ профилактики послеоперационного спаечного процесса органов малого таза
RU2749435C1 (ru) * 2020-11-27 2021-06-10 Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" Способ лечения энтеральной недостаточности при воспалительных и травматических повреждениях брюшины

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7629594A (en) * 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
JPH11510511A (ja) * 1995-08-10 1999-09-14 メルク エンド カンパニー インコーポレーテッド 2,5−置換アリールピロール、この化合物を含有する組成物及び使用方法
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5894971A (en) 1998-02-02 1999-04-20 Huang; Te Chien Tool holder for attaching tools to user's hand
US6521223B1 (en) 2000-02-14 2003-02-18 Genzyme Corporation Single phase gels for the prevention of adhesions
HUP0303763A3 (en) * 2000-08-17 2004-06-28 Pfizer Substituted imidazoles as tafia inhibitors, process for their preparation and pharmaceutical compositions containing them
AU2003249977A1 (en) * 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
WO2004060405A2 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
PT1928454E (pt) * 2005-05-10 2014-12-04 Intermune Inc Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress
CA2625426A1 (en) * 2005-09-22 2007-03-29 Hadasit Medical Research Services & Development Limited Dextran and arabinogalactan conjugates of therapeutically active compounds
CA2668731A1 (en) * 2006-11-09 2008-05-15 Tobias Gabriel Kinase inhibitors and methods for using the same
WO2008099829A1 (ja) * 2007-02-14 2008-08-21 Japan Science And Technology Agency 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤
CN101848739A (zh) * 2007-08-28 2010-09-29 T·阿萨纳夏季斯 手术用水凝胶
RU2363476C1 (ru) 2007-12-20 2009-08-10 Марина Сергеевна Гомон Способ профилактики образования послеоперационных спаек
WO2009103821A2 (de) * 2008-02-23 2009-08-27 Virologik Gmbh Mittel zur behandlung von virusinfektionen
US8205286B1 (en) 2008-10-21 2012-06-26 Milagros Diaz Pillow for female breasts
KR20170034950A (ko) * 2011-05-17 2017-03-29 조인트 스톡 컴퍼니 “파르마신세즈” 부착과정의 예방과 치료를 위한 p38 MAP 키나아제 저해제 조성물
CA2846143A1 (en) 2013-03-13 2014-09-13 Evan J. Falck Helmet pillow

Also Published As

Publication number Publication date
DK2716684T3 (da) 2019-09-30
SI2716684T1 (sl) 2019-11-29
CR20130600A (es) 2014-04-29
CA2836268A1 (en) 2012-11-22
NZ618882A (en) 2016-03-31
PE20141161A1 (es) 2014-10-01
CO6801779A2 (es) 2013-11-29
US20190125886A1 (en) 2019-05-02
NI201300124A (es) 2014-02-25
EP3569636A1 (en) 2019-11-20
US10172952B2 (en) 2019-01-08
AP3694A (en) 2016-04-30
JP2014515057A (ja) 2014-06-26
IL229423A0 (en) 2014-01-30
ZA201308542B (en) 2014-07-30
CL2013003305A1 (es) 2014-07-18
RU2582975C2 (ru) 2016-04-27
BR112013029616A2 (pt) 2020-08-25
AU2012257347A1 (en) 2014-01-09
IL229423B (en) 2018-04-30
PL2716684T3 (pl) 2020-01-31
PH12013502381A1 (en) 2014-02-10
MA35189B1 (fr) 2014-06-02
EP2716684A1 (en) 2014-04-09
RS59382B1 (sr) 2019-11-29
WO2012156938A1 (ru) 2012-11-22
CN103534293A (zh) 2014-01-22
EA025493B1 (ru) 2016-12-30
KR20140074259A (ko) 2014-06-17
SV2013004582A (es) 2018-11-12
CY1122190T1 (el) 2020-11-25
MX382507B (es) 2025-03-13
DOP2013000266A (es) 2014-06-01
JP5936683B2 (ja) 2016-06-22
KR20170034950A (ko) 2017-03-29
RU2013155582A (ru) 2015-06-27
US10493164B2 (en) 2019-12-03
AU2015213303A1 (en) 2015-09-03
US20140079663A1 (en) 2014-03-20
EA201301275A1 (ru) 2014-03-31
AU2017221883B2 (en) 2019-06-20
AP2013007258A0 (en) 2013-11-30
MX369019B (es) 2019-10-24
EP2716684B1 (en) 2019-06-26
CA2836268C (en) 2018-07-03
BR112013029616B1 (pt) 2022-09-20
AU2017221883A1 (en) 2017-09-28
PH12013502381B1 (en) 2021-03-26
EP2716684A4 (en) 2015-07-15
CN103534293B (zh) 2015-10-21
LT2716684T (lt) 2019-09-25
MX2013013409A (es) 2014-07-11
HK1189012A1 (en) 2014-05-23
JP2016175931A (ja) 2016-10-06
GEP201706614B (en) 2017-02-10

Similar Documents

Publication Publication Date Title
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP13012569A (es) Formulación de premezcla de dexmedetomidina
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
BR112015018168A2 (pt) inibidores de rock suaves
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
DOP2015000170A (es) Compuestos químicos
DOP2016000253A (es) Nuevos compuestos
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
PE20151607A1 (es) Formulaciones de compuestos organicos
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
MX2019011386A (es) Compuestos, composiciones farmaceuticas y un metodo para la profilaxis y tratamiento del proceso de adhesion.
CR20160432A (es) Inhibidores de las vías de señalización de wnt
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.